No abstract available.
Nasal Bone*

The purpose of this study was to compare the cytotoxicity by MTT test and genotoxicity by Ames test of new calcium phosphate-based root canal sealers (CAPSEAL I, CAPSEAL II) with commercially available resin-based sealers (AH 26, AH Plus), zinc oxide eugenol-based sealers (Tubliseal EWT, Pulp Canal Sealer EWT), calcium hydroxide-based sealer (Sealapex), and tricalcium phosphate based sealers (Sankin Apatite Root Canal Sealer I, II, III). According to this study, the results were as follows: 1. The extracts of freshly mixed group showed higher toxicity than those of 24 h set group in MTT assay (p < 0.001). 2. CAPSEAL I and CAPSEAL II were less cytotoxic than AH 26, AH Plus, Tubliseal EWT, Pulp Canal Sealer EWT, Sealapex and SARCS II in freshly mixed group (p < 0.01). 3. AH 26 in freshly mixed group showed mutagenicity to TA98 and TA100 with and without S9 mix and AH Plus extracts also were mutagenic to TA100 with and without S9 mix. 4. Tubliseal EWT, Pulp Canal Sealer EWT and Sealapex in freshly mixed group were mutagenic to TA100 with S9 mix. 5. Among those of 24 h set groups, the extracts of SARCS II were mutagenic to TA98 with and without S9 mix and AH 26 showed mutagenic effects to TA98 with S9 mix. 6. No mutagenic effect of CAPSEAL I and CAPSEAL II was detected. 7. There is no statistically significant difference between CAPSEAL I and CAPSEAL II at MTT assay and Ames test in both freshly mixed group and 24 h set group.
Calcium* ; Dental Pulp Cavity* ; Zinc Oxide

No abstract available.
Calcium* ; Dental Pulp Cavity*

No abstract available.
Adhesives* ; Dental Pulp Cavity* ; Dentin* ; Gutta-Percha*

No abstract available.
Dental Pulp Cavity

From May, 1975 to August, 1986, we experienced 21 patients with ruptured aneurysm of the sinus of Valsalva. 1) Their ages ranged from 15 to 52 years with a mean age of 26.7 years, and 14 patients were male and 7 patients were female. Among 18 cases of which aneurysms occurred on the right sinus of Valsalva, 15 cases (83%) ruptured into the right ventricle, 1 case (6%) ruptured into the right atrium and 2 cases (11%) ruptured into the pulmonary artery. All 3 cases of which aneurysms occurred on the noncoronary sinus ruptured into the right atrium. 2) Clinical symptoms consisted of dyspnea (95%), palpitation (81%), chest pain (43%), orthopnea (33%), cough (14%), hemoptysis (5%), oliguria (5%), and fever (5%). In all patients continuous heart murmur was audible. Hepatomegaly (48%), pulmonary basal rale (14%), and pretibial pitting edema (19%) were also observed. 3) In all patients diagnosis was made with cardiac catheterization and angiography, and confirmed by operation excetpt one case. 4) Among 20 patients who had been performed corrective surgery, ventricular septal defect was observed in 16 patients (85%), aortic insufficiency in 5 patients (25%), pulmonary infundibular stenosis in 1 patient (5%), patent foramen ovale in 1 patient (5%), and tricuspid insufficiency in 1 patient (5%). Ventricular septal defect was observed in all 16 patients whose aneurysms of the right coronary sinus of Valsalva ruptured into the right ventricle and the pulmonary artery. 5) All patients survived operation, and no postoperative complication was found except 1 patient to whom reoperation was performed because of postoperative aortic insufficiency and detachment of the patch closure for ventricular septal defect. There was symptomatic improvement in all patients.
Aneurysm ; Aneurysm, Ruptured* ; Angiography ; Cardiac Catheterization ; Cardiac Catheters ; Chest Pain ; Coronary Sinus ; Cough ; Diagnosis ; Dyspnea ; Edema ; Female ; Fever ; Foramen Ovale, Patent ; Heart Atria ; Heart Murmurs ; Heart Septal Defects, Ventricular ; Heart Ventricles ; Hemoptysis ; Hepatomegaly ; Humans ; Male ; Oliguria ; Postoperative Complications ; Pulmonary Artery ; Pulmonary Subvalvular Stenosis ; Reoperation ; Respiratory Sounds ; Sinus of Valsalva*

Mineral trioxide aggregate (MTA) would influence healing of periapical tissues by modulating the production of growth factors and cytokines from PDL fibroblasts, however, the studies are insufficient. Therefore, the purpose of this study was to monitor the expression of transforming growth factor-beta1 (TGF- beta1), fibroblast growth factor-2 (FGF-2), and interleukin-6 (IL-6) from PDL fibroblasts in the presence of MTA. The human PDL fibroblasts were seeded onto the set MTA or IRM at a level of 1 x 10(5) cells per unit well, and further incubated for 6, 12, 24, and 48 hours. The levels of TGF-beta1, FGF-2, and IL-6 from the supernatant were measured by enzyme-linked immunosorbent assay (ELISA). The data were analyzed using one-way ANOVA. The level of TGF-beta1 was down-regulated when the cells were grown in the presence of MTA except at 6 hours. The levels of FGF-2 release were significantly suppressed when PDL fibroblasts were grown in the presence of MTA or IRM at all time intervals (p < 0.05). The expressions of IL-6 from MTA treated cells were comparable to those of untreated control cells throughout the observation periods. We presume that this material inhibits the stimulatory function of growth factors on granulation tissue formation and in turn, it promotes the healing process modulated by other bone-remodeling cells.
Cytokines ; Enzyme-Linked Immunosorbent Assay ; Fibroblast Growth Factor 2 ; Fibroblasts* ; Granulation Tissue ; Humans* ; Intercellular Signaling Peptides and Proteins* ; Interleukin-6 ; Periapical Tissue ; Periodontal Ligament* ; Transforming Growth Factor beta1 ; Pemetrexed

Mineral trioxide aggregate (MTA) would influence healing of periapical tissues by modulating the production of growth factors and cytokines from PDL fibroblasts, however, the studies are insufficient. Therefore, the purpose of this study was to monitor the expression of transforming growth factor-beta1 (TGF- beta1), fibroblast growth factor-2 (FGF-2), and interleukin-6 (IL-6) from PDL fibroblasts in the presence of MTA. The human PDL fibroblasts were seeded onto the set MTA or IRM at a level of 1 x 10(5) cells per unit well, and further incubated for 6, 12, 24, and 48 hours. The levels of TGF-beta1, FGF-2, and IL-6 from the supernatant were measured by enzyme-linked immunosorbent assay (ELISA). The data were analyzed using one-way ANOVA. The level of TGF-beta1 was down-regulated when the cells were grown in the presence of MTA except at 6 hours. The levels of FGF-2 release were significantly suppressed when PDL fibroblasts were grown in the presence of MTA or IRM at all time intervals (p < 0.05). The expressions of IL-6 from MTA treated cells were comparable to those of untreated control cells throughout the observation periods. We presume that this material inhibits the stimulatory function of growth factors on granulation tissue formation and in turn, it promotes the healing process modulated by other bone-remodeling cells.
Cytokines ; Enzyme-Linked Immunosorbent Assay ; Fibroblast Growth Factor 2 ; Fibroblasts* ; Granulation Tissue ; Humans* ; Intercellular Signaling Peptides and Proteins* ; Interleukin-6 ; Periapical Tissue ; Periodontal Ligament* ; Transforming Growth Factor beta1 ; Pemetrexed

BACKGROUND: Platelet plays an important role in the pathogenesis of acute coronary syndrome. Platelet glycoprotein IIb III a is the receptor for fibrinogen, and it plays an important role in the platelet aggregation. It was reported that polymorphism of the platelet glycoprotein III a (PlA1/A2) is related to acute coronary syndrome, especially in young patients. The aims of this study is to evaluate the relationship between platelet glycoprotein III a polymorphism and acute coronary syndrome in Koreans. METHOD: We studied total 208 patients (M: F=131 : 77, mean ages : 57.2+/-9.7). Acute coronary group comprised 110 patients, who underwent coronary angiography with the impression of acute myocardial infarction or unstable angina. Normal group comprised 98 patients who had no significant angiographic lesion. Genomic DNA was extracted from peripheral blood. To determine the frequency of PlA1/A2 genotype, polymerase chain reaction (PCR) was done and the product was restricted with Msp I. 3% gel electrophoresis showed Restriction Fragment Length Polymorphism (RFLP). Clinical profile and risk factor were also reviewed. RESULT: One patient in the acute coronary group is PlA1/A2 heterozygote and all the other are PlA1 homozygote. In normal group, all patients are PlA1 homozygote. The genotypic frequency of PlA1/A2 is consistent with the previous study. CONCLUSION: The genotype frequency of platelet glycoprotein III a gene polymorphism in Koreans is different from that of Caucasian. The allele frequencies of platelet glycoprotein III a is not different between acute coronary syndrome patient and normal control group. Platelet glycoprotein III a polymorphism may not be an hereditary risk factor in Koreans.
Acute Coronary Syndrome* ; Angina, Unstable ; Blood Platelets* ; Coronary Angiography ; DNA ; Electrophoresis ; Fibrinogen ; Gene Frequency ; Genes, vif ; Genotype ; Glycoproteins* ; Heterozygote ; Homozygote ; Humans ; Integrin beta3 ; Myocardial Infarction ; Platelet Aggregation ; Polymerase Chain Reaction ; Polymorphism, Restriction Fragment Length ; Risk Factors

BACKGROUND: Platelet plays an important role in the pathogenesis of acute coronary syndrome. Platelet glycoprotein IIb III a is the receptor for fibrinogen, and it plays an important role in the platelet aggregation. It was reported that polymorphism of the platelet glycoprotein III a (PlA1/A2) is related to acute coronary syndrome, especially in young patients. The aims of this study is to evaluate the relationship between platelet glycoprotein III a polymorphism and acute coronary syndrome in Koreans. METHOD: We studied total 208 patients (M: F=131 : 77, mean ages : 57.2+/-9.7). Acute coronary group comprised 110 patients, who underwent coronary angiography with the impression of acute myocardial infarction or unstable angina. Normal group comprised 98 patients who had no significant angiographic lesion. Genomic DNA was extracted from peripheral blood. To determine the frequency of PlA1/A2 genotype, polymerase chain reaction (PCR) was done and the product was restricted with Msp I. 3% gel electrophoresis showed Restriction Fragment Length Polymorphism (RFLP). Clinical profile and risk factor were also reviewed. RESULT: One patient in the acute coronary group is PlA1/A2 heterozygote and all the other are PlA1 homozygote. In normal group, all patients are PlA1 homozygote. The genotypic frequency of PlA1/A2 is consistent with the previous study. CONCLUSION: The genotype frequency of platelet glycoprotein III a gene polymorphism in Koreans is different from that of Caucasian. The allele frequencies of platelet glycoprotein III a is not different between acute coronary syndrome patient and normal control group. Platelet glycoprotein III a polymorphism may not be an hereditary risk factor in Koreans.
Acute Coronary Syndrome* ; Angina, Unstable ; Blood Platelets* ; Coronary Angiography ; DNA ; Electrophoresis ; Fibrinogen ; Gene Frequency ; Genes, vif ; Genotype ; Glycoproteins* ; Heterozygote ; Homozygote ; Humans ; Integrin beta3 ; Myocardial Infarction ; Platelet Aggregation ; Polymerase Chain Reaction ; Polymorphism, Restriction Fragment Length ; Risk Factors